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Abstract
Background: Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50–60%
of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy.
Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti-CCP) have been evaluated as biomarkers of
response but the results have shown limited consistency. Anti-carbamylated protein (anti-CarP) and anti-peptidylarginine
deiminase type 4 (anti-PAD4) antibodies have been much less studied. Despite being linked to common immune
processes, the interaction between these markers has not been evaluated yet. Our aim was to analyze the interaction
between these four antibodies in relation to the response to anti-TNF therapy.
Methods: For this objective, a prospective cohort of n = 80 RA patients starting anti-TNF therapy was recruited. Serum
determinations at baseline were performed for RF, anti-CCP, anti-CarP and anti-PAD4 antibodies using enzyme-linked
immunosorbent assays (ELISA). The clinical response to anti-TNF therapy was determined at week 12 using the change in
DAS28 score. Association was performed using multivariate linear regression adjusting for baseline DAS28, sex and age.
Results: The interaction between pairs of antibodies was tested by the addition of an interaction term. We found two
highly significant antibody interactions associated with treatment response: anti-CarP with anti-PAD4 (p = 0.0062), and
anti-CCP with RF (p = 0.00068). The latter antibody interaction was replicated in an independent retrospective cohort of
RA patients (n = 199, p = 0.04).
Conclusions: The results of this study suggest that antibody interaction effects are important factors in the response to
anti-TNF therapy in RA.
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Background
Rheumatoid arthritis (RA) is the most common chronic
inflammatory arthritis, with a Worldwide prevalence of
0.5–1%. Tumor necrosis factor (TNF) is a proinflamma-
tory cytokine that is central to the inflammatory process
of RA. Systemic blocking of this cytokine has proven to
be a highly efficacious approach to control the disease
activity [1]. Despite this major therapeutic advance, up
to 40% of RA patients treated with a TNF blocking agent
don’t show a significant clinical improvement. Very little
knowledge exists on the factors that determine this
unfavorable response, and biomarkers have yet to be
identified.
RA is characterized by the expression of antibodies
against self-antigens, and consequently they have been
among the first biomarkers to be evaluated for associ-
ation with treatment response. Antibodies against the Fc
portion of immunoglobulin G –rheumatoid factor (RF)-
and against cyclic citrullinated peptides (anti-CCP) are
currently the two most relevant diagnostic tests for RA
[2]. Both autoantibodies have been clearly associated to
unfavorable prognosis [3]. However, their association to
the response to anti-TNF therapy is much less clear.
Previous studies have shown inconclusive or conflicting
results [4–6]. Consequently, interest has shifted in ana-
lyzing more recently discovered antibodies as potential
biomarkers for treatment response.
Anti-peptidylarginine deiminase type 4 (anti-PAD4)
antibodies [7] and anti-carbamylated protein (anti-CarP)
antibodies [8] are recent markers in RA. Anti-PAD4
antibodies, although not specific for RA, have been asso-
ciated to a more severe disease phenotype [9]. There is
yet scarce data on the association of anti-PAD4 in anti-
TNF response. A first small study on 40 patients found
that patients positive for this antibody had a worse re-
sponse to therapy [10]. A more recent study involving
triple DMARD and anti-TNF therapy treated patients,
suggested that anti-PAD4 positive patients had instead a
more favorable response [11]. However, the association
was not tested individually for each drug arm, so the
specific association to TNF blocking is unclear. Anti-
CarP antibodies occur in up to 40% of RA patients and,
like anti-CCPs, they can appear several years before the
onset of the disease. To date, anti-CarP antibodies have
not been tested for association with the response to
anti-TNF therapy in RA.
The presence of previous conflicting results could be
an indication that a more complex relationship exists be-
tween antibodies and the response to anti-TNF therapy
in RA. From a biological perspective, anti-CarP, anti-
PAD4, RF and anti-CCP target proteins involved in
closely related biological processes. The simultaneous
expression of two or more of these antibodies could
therefore represent a higher load of specific pathogenic
mechanisms. Recent experimental evidence supports the
presence of this type of pathogenic interactions between
RA autoantibodies [12]. From a clinical perspective, the
presence of synergic effects between antibodies could
translate into stronger responses to therapy. In the
present study we have addressed this question and ana-
lyzed, for the first time, the association of antibody inter-
actions with the response to anti-TNF therapy.
Methods
Patients and samples
A prospective cohort of n = 80 RA patients was recruited
from 11 university hospitals from Spain. Enrolled pa-
tients fulfilled the ACR/EULAR 2010 classification cri-
teria for RA [2] and were starting an anti-TNF therapy.
All patients had an active disease at baseline, described
as a 28-joint Disease Activity Score (DAS28) ≥ 3.2. The
same day of treatment initiation, blood samples were ob-
tained and the plasma fraction separated and stored at
− 80 °C until analysis.
The validation dataset consisted on a retrospective co-
hort of n = 199 RA patients that were recruited by the
IMID Consortium, a network of rheumatology depart-
ments from n = 15 university hospitals in Spain [13]. All
patients fulfilled the ACR/EULAR 2010 classification cri-
teria for RA, and the primary response to anti-TNF ther-
apy at week 12 was collected. Plasma samples were
processed following the same procedure.
Antibody measurements
The four antibodies were analyzed using enzyme-linked
immunosorbent assays (ELISA). RF and anti-CCP were
measured using the IBL International and the Euro
Diagnostica anti-CCP2 ELISA kits, respectively. Positiv-
ity for anti-CCP and RF were defined according to the
manufacturer’s protocols (≥ 18 U/ml and ≥ 25 U/ml for
RF and anti-CCP, respectively). Anti-PAD4 titers were
measured using the PAD4 autoantibody ELISA kit (Cay-
man Chemical). Anti-carbamylated proteins IgG auto-
antibodies (anti-CarP) were determined using a home-
made ELISA test using as antigen carbamylated fetal calf
serum (FCS). A non-carbamylated version of the FCS
was used to control for homocitrulline specificity. Re-
activity to non-modified FCS was subtracted from the
reactivity to carbamylated FCS and a standard curve of
serial dilutions of a pool of four positive samples was
used to convert optical density values to arbitrary units
(AU). Compared to IgM-RF and anti-CCP2, there is no
established threshold for positivity for anti-PAD4 or
anti-CarP biomarkers, and antibody titers were directly
used to test for association with anti-TNF response.
In the validation cohort, anti-CCP was measured using
an electrochemiluminescence assay (Cobas, Roche) and
the RF was determined using an immunoturbidimetric
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method (Cobas, Roche). Positivity thresholds were de-
fined using the manufacturer’s protocol (≥ 17 U/ml
and ≥ 14 U/ml for anti-CCP and RF, respectively).
Statistical analysis
The primary outcome measure was the change in the
DAS28 score (ΔDAS28) between baseline and 12
weeks of anti-TNF therapy [14]. The association be-
tween anti-CarP, PAD4, RF and anti-CCP antibodies
and treatment response was determined using multi-
variate linear regression. The multivariate model in-
cluded sex, age and the baseline DAS28 measure, as
described previously [4].
Interaction testing was performed by including an add-
itional interaction term in the multivariate regression
model. All pairwise interaction models between the four
biomarkers were tested (n = 6). Multiple testing signifi-




Baseline characteristics of the prospective patient cohort
are summarized in Table 1. Clinical measures are com-
parable to previous RA cohorts. The four autoantibody
titers were determined in 100% of the patients. 65% of
the RA patients were positive for RF and 72% of for
anti-CCP. An average reduction of 1.96 (+/− 1.33) points
in the DAS28 score was observed for the global cohort,
which is consistent with previous studies [15].
Association of antibodies with anti-TNF response
Multivariate linear regression was used to simultaneously
test for association between anti-CCP, RF, anti-CarP and
anti-PAD4 antibodies and treatment response. At the
single-marker level, none of the autoantibodies were
found to be significantly associated with an improvement
in the DAS28 (Supplementary Table S1). We next tested
for the presence of interaction effects between all six pair-
wise antibody combinations in relation to treatment re-
sponse. We found a highly significant antibody interaction
between anti-CarP and anti-PAD4 (P = 0.0062), and be-
tween anti-CCP and RF (P = 0.00068) with anti-TNF re-
sponse (Table 2). anti-CarP:anti-PAD4 interaction was
associated with a worse response to therapy (interaction
coefficient β < 0) and anti-CCP:RF interaction with a bet-
ter response to TNF blocking (β > 0). The remaining four
pairwise antibody interactions were not significant (P >
0.05). After adjusting for multiple testing, anti-CarP:anti-
PAD4 and anti-CCP:RF interactions remained statistically
significant (P = 0.0041 and P = 0.037, respectively).
Using an independent cohort of 199 RA patients, we
replicated the interaction between anti-CCP and RF
(P = 0.044, Fig. 1). Like in the prospective cohort, the
interaction was also found to be positive, indicating that
the simultaneous presence of both antibodies is associ-
ated with a better response to anti-TNF therapy.
Table 1 Baseline characteristics of the prospective RA patient cohort
Baseline variable Total
(n = 80)
Responders (n = 67) Non-Responders (n = 13)
Age, years (mean ± SD) 54.2 ± 11.93 53.12 ± 11.65 59.7 ± 12.32
Gender (Female,n %) 66 (82.5) 54 (80.6) 12 (92)
Previous csDMARDs (mean ± SD) 1.85 ± 1.28 1.82 ± 1.24 2 ± 1.53
Disease duration, years (median/IQR) 9.74 (9.25) 9.24 (9.5) 12.31 (11.41)
ESR, mm/h (median/IQR) 35.1 (28.75) 36.52 (34) 27.7 (21.17)
CRP, mg/dL (median/IQR) 1.63 (1.27) 1.63 (1.23) 1.62 (1.47)
MTX dosage (mean mg/week) 18.46 18.25 19.64
Prednisone use (n, %) 60 (75) 50 (74.6) 10 (77)
Smoking (n, %)
Never 54 (67.5) 44 (65.7) 10 (77)
Past 10 (12.5) 6 (9) 3 (23)
Current 16 (20) 17 (25.3) 0 (0)
Adalimumab 16 (20) 15 (22.4) 1 (8)
Certolizumab 24 (30) 21 (31.3) 3 (23)
Etanercept 19 (23.75) 16 (23.4) 3 (23)
Golimumab 21 (26.25) 15 (22.4) 6 (46)
Clinical and epidemiological characteristics of the prospective cohort. Patients are shown globally and split according to the EULAR response at week 12 (Good
and Moderate responders aggregated into a unique Responder group). MTX methotrexate; csDMARDs conventional synthetic DMARDs; IQR interquartile range;
SD standard deviation
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Discussion
The identification of factors associated with the response
to anti-TNF therapy is a major objective for treatment
personalization in RA. Diagnostic autoantibodies, like
rheumatoid factor and anti-CCP, are appealing for this
task since they are already integrated into the standard
clinical routine. However, conflicting results have been
reported and their association to treatment response to
anti-TNF is yet not clear. We hypothesized that this
inconsistency could be due to the presence of interaction
effects between the autoantibodies. In the present study
we have tested this hypothesis for the first time. Using a
prospective cohort of RA patients starting anti-TNF
therapy, we have found that the interaction between
anti-CCP and RF and the interaction between anti-CarP
and anti-PAD4 antibodies are both strongly associated
with the clinical response at week 12. The present re-
sults suggest that interactions between antibodies are
Table 2 Association results for RA antibody interactions with anti-TNF response
Regression coefficient (95%CI),
P-value

















































Each row shows the association results for each of the six possible pairwise interactions between the four RA antibodies and anti-TNF treatment response,
adjusting for baseline DAS28, sex and age. Regression coefficients (β value) with 95% confidence intervals (CI) and P values for association are shown for the
interaction term (first column) and for the independent effect of each antibody (second and third columns). In bold, interaction P-values that are significant after
correcting for multiple testing. A highly significant interaction was found for anti-CCP:RF and anti-PAD4:anti-CarP interactions with anti-TNF response. None of the
remaining four antibody interactions showed a significant association, even at the nominal (P < 0.05) level
Fig. 1 Validation study of the anti-CCP and RF interaction and anti-TNF response in RA. Forest plot showing the regression coefficients and 95%
confidence intervals of the variables in the linear model testing the association of the two antibody combination with the response to anti-TNF
therapy at week 12. Like in the prospective patient cohort, the interaction between anti-CCP and RF is statistically significant and positively
associated with anti-TNF response (Beta:1.06 (0.03 to 2.10); P < 0.05). Anti-CCP:RF: regression coefficient capturing the interaction effect
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important in the response to anti-TNF therapy, and pro-
vide an explanation for the previous conflicting
evidence.
Our study shows that the presence of both anti-CCP
and RF antibodies is needed for a favorable response to
anti-TNF therapy. Several previous studies have analyzed
the association of either antibody in relation with the re-
sponse to anti-TNF drugs. The results, however, have
been largely inconsistent or inconclusive [16]. In those
few studies where both antibodies were determined, the
presence of interactions was not evaluated. Here we
show that, when the interaction is considered, a strong
and positive association between these two classic anti-
bodies and the clinical response emerges. From a statis-
tical perspective, when interaction effects are present
and are strong, not taking them into account in the as-
sociation model can lead to inconsistent findings [17].
Failing to take this into account could therefore explain
the lack of reproducibility of previous studies with anti-
CCP and RF and treatment response.
The interaction association identified between anti-
CCP and RF with the response to anti-TNF therapy is in
accordance with recent findings at the functional level.
In a recent study, macrophages -the main producers of
TNF in the RA joint- have been shown to secrete much
higher TNF cytokine levels when stimulated with both
anti-CCP and RF antibodies than when stimulated with
anti-CCP alone [12]. According to these results, disease
activity in RA patients that express both anti-CCP and
RF might be partially due to the overexpression of TNF
by macrophages reacting strongly to the combination of
the two antibodies. Instead, in patients expressing only
one of the antibodies or in seronegative patients, this
synergic production of TNF by the synovial macrophage
will not occur, and other inflammatory pathways will
therefore have a more predominant role in disease activ-
ity. Our results show that, although still effective in
some patients, anti-TNF therapy has a much less pro-
nounced therapeutic effect in patients with only one
antibody compared to patients positive for both anti-
CCP and RF.
In our study we also found that the interaction be-
tween anti-CarP and anti-PAD4 is associated to anti-
TNF response. In this case, we found that the higher the
expression of both antibodies, the worse the patients
responded to TNF blocking. Compared to anti-CCP and
RF, these two antibodies do not physically interact at the
molecular level. However, the two antibodies share a
strong association to neutrophil activity. PAD4 is re-
sponsible for most of the citrullinated epitopes in RA
[18] and is specifically expressed in neutrophils. Protein
carbamylation is caused by an increase in tissue cyanate
due to the activity of neutrophil myeloperoxidase during
inflammation in RA. A higher abundance of both
antibodies therefore suggests a more predominant role
of neutrophils in RA pathology. According to our re-
sults, patients with a strong neutrophil-mediated inflam-
mation are less sensitive to therapeutic TNF blocking.
This is in line with recent experimental evidence show-
ing that neutrophil activation and TNF have independ-
ent effects in RA pathology [19]. New therapies that
directly affect neutrophil activation like, granulocyte-
macrophage colony-stimulating factor blocking, are cur-
rently under way in RA [20]. Our results suggest that
the simultaneous analysis of anti-PAD4 and anti-CarP
antibodies could be a useful biomarker of response in
this new therapeutic approach.
The present study has limitations. Despite most
previous studies analyzing the association of anti-
bodies to anti-TNF response have used similar or
smaller sample sizes, the number of patients used in
our prospective study is relatively modest. Having a
larger patient cohort would have enabled a more pre-
cise estimation of the interaction effects, with nar-
rower confidence intervals. To this regard, while the
quantitative nature of the ΔDAS28 can help increase
the power to identify biomarkers of drug efficacy,
small improvements in DAS28 might not have a
translation into clinically meaningful responses. More
patient data on the four antibodies will help to better
define this boundary. Finally, the comparison of the
interaction association between different types of anti-
TNF drugs could not be explored. There is evidence
that TNF blocking agents work through biological
mechanisms that are not entirely overlapping [21, 22].
An individual analysis of each drug type might reveal
stronger interactions and better biomarker utility. For
this aspect to be adequately tested, larger drug-
specific prospective patient cohorts will need to be
analyzed.
Conclusion
In summary, in the present study we have found that RA
antibodies show significant interaction effects with the
response to anti-TNF therapy. The observed interactions
are in line with pathogenic mechanisms recently de-
scribed in RA. Our findings also provide an explanation
for the lack of consistency observed in previous studies,
in which antibodies were analyzed independently. These
results leverage the potential of antibodies as biomarkers
for anti-TNF response in RA.
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